Cameron Gray - 14 Jun 2022 Form 4 Insider Report for Cue Biopharma, Inc. (CUE)

Role: Director
Signature: /s/ Cameron Gray by Colin Sandercock attorney-in-fact
Issuer symbol: CUE
Transactions as of: 14 Jun 2022
Net transactions value: +$1.3
Form type: 4
Filing time: 16 Jun 2022, 16:01:21 UTC
Previous filing: 05 Jan 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CUE	Common Stock	Exercise of in-the-money or at-the-money derivative security	$165,000	+61,111	+9%	$2.70	738,611	14 Jun 2022	Direct
transaction	CUE	Common Stock	Tax liability	$164,998	-51,562	-7%	$3.20	687,049	14 Jun 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CUE	Warrants	Exercise of in-the-money or at-the-money derivative security	$0	-61,111	-100%	$0.000000^*	0	14 Jun 2022	Common Stock	61,111	$2.70	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On June 14, 2022, the reporting person exercised a warrant to purchase 61,111 shares of the Issuers common stock for $2.70 a share. The reporting person paid the exercise price on a cashless basis, resulting in the Issuer withholding of 51,562 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 9,549 shares.